DEPARTMENT.FACULTY

photo
Dr. Imtiyaz Yousuf
  • DEPARTMENT_STAFF.QUALIFICATION

    PhD MSc JRF (NET)

  • DEPARTMENT_STAFF.DESIGNATION

    Assistant Professor

  • DEPARTMENT_STAFF.THRUST_AREA

    Bioinorganic, Synthetic Inorganic Chemistry, Organometallic Chemistry, Crystallography

  • DEPARTMENT_STAFF.ADDRESS

    Department of Chemistry,

  • DEPARTMENT_STAFF.MOBILE

  • DEPARTMENT_STAFF.EMAIL

    imtiyazchem@gmail.com

DEPARTMENT_STAFF.COMPLETE_CV
DEPARTMENT_STAFF.PROFILE

Dr. Imtiyaz Yousuf did his B.Sc. and M.Sc. in chemistry from the University of Kashmir, J & K. He was awarded UGC-CSIR JRF (NET) fellowship in Dec. 2010. He joined the Department of Chemistry, AMU as Junior Research Fellow (JRF) for his Ph.D studies in Inorganic Chemistry and was subsequently upgraded to Senior Research Fellow (SRF) in 2013. In 2015, he was awarded PhD in Chemistry. Later, in 2015, he joined the Department Of Chemistry, A.M.U, Aligarh as Assistant Professor. His research interests include the design and synthesis of novel metal-based complexes and study their biological applications. His recent interests include design and syntheses of targeted metal-based Anticancer Complexes with high antitumor efficacy and lower systemic toxicity. He has presented his work in many national and International Conferences. He has also published many research papers in area of therapeutic metallodrugs in many international journals. He is also serving as a potential reviewer and editorial board member of many journals of international repute. He is also a life member of many national and international scientific and academic bodies.

  1. Publication

    Key Publications

    An overview of advancement of organoruthenium(II) complexes as

    prospective anticancer agent

    Coord. Chem. Rev., 487 (2023) 215169.   (I.F = 24.83)


    Syntheses, Structural Characterization, and Cytotoxicity Assessment of Novel Mn(II) and Zn(II) Complexes of Aroyl-Hydrazone Schiff Base  Ligand, 

    ACS Omega, (2023), 8, 3, 3026–3042  (IF= 4.13)

    Synthesis, structural characterization and in vitro cytotoxicity assessment of new mononuclear Cu(II) and Co(II) complexes against MDA–MB–231, HCC–1806 and HT–29 cancer cell lines, Polyhedron, 229 (2023) 116189. (IF= 3.04)


    Structure elucidation of a bimetallic ?-hydroxo-bridged Cu(II)-lufenamate-bpy complex and cytotoxic evaluation against MDA-MB-231 and A549 carcinoma cell lines, 
    Appl. Organomet. Chem., (2022) 36, e6906. 
    (IF= 4.07)

    Mixed Ni(II) and Co(II) complexes of Nalidixic acid drug: Synthesis, characterization, DNA/BSA binding profile and in vitro cytotoxic evaluation against MDA-MB-231 and HepG2 cancer cell lines, 
    Spectro. Chim. Acta. Mol. & Biomol. Spectr., 271 (2022) 120910. (IF= 4.831)

    Synthesis, structural characterization and in vitro cytotoxic evaluation of mixed Cu(II)/Co(II) levofloxacin–bipyridyl complexes. 
    Inorg. Chim.Acta., 532 (2022) 1207572. 
    (IF= 3.11)

    Metal complexes of NSAIDs as potent anti-tumor chemotherapeutics: Mechanistic insights into cytotoxic activity via multiple pathways primarily by inhibition of COX–1 and COX–2 enzymes, 
    Coord. Chem. Rev.  453 (2022) 214316.   
    (IF= 24.831)

    Advancement of metal compounds as therapeutic and diagnostic metallodrugs: Current frontiers and future perspectives. Coord. Chem. Rev. 445 (2021) 214104  (IF= 24.831)

    Structural characterization, theoretical investigation and sensing activity of a novel Cu(II)–based 1D metal coordination polymer. Inorg. Chem. Commun., 126 (2021) 108473 (I.F. = 3.425)


    Synthesis, structural investigations, and cytotoxic evaluation of a half?sandwich Ru(II)-arene complex.  Appl Organomet Chem., 2020, e6090 (I.F = 4.10)


    Recent advances in metallodrug-like molecules targeting non-coding RNAs in cancer chemotherapy,  Coord. Chem. Rev., 2019, 387, 47–59. (IF= 24.83)

    Design and synthesis of a DNA intercalative half-sandwich organoruthenium(II)–chromone complex: cytotoxicity evaluation and topoisomerase I? inhibition assay

    New J. Chem., 2019, 43, 5475-5487 (I. F. = 3.53)


     Single X-ray crystal structure, DFT studies and topoisomerase I inhibition activity of a tailored ionic Ag(I) nalidixic acid–piperazinium drug entity specific for pancreatic cancer cells.  New J. Chem., 2018, 42, 506-519. (I. F. = 3.53)

    Mechanistic insights of a novel chromone–appended Cu(II) anticancer drug entity: In vitro binding profile with DNA/RNA substrates and cytotoxic activity against MCF–7 and HepG2 cancer cells.  Dalton Trans. 2015, 44, 10330. (I. F. = 4.39)


     Enantiomeric fluoro–substituted benzothiazole Schiff base–valine Cu(II)/Zn(II) complexes as chemotherapeutic agents: DNA binding profile, cleavage activity, MTT assay and cell imaging studies.  J. Photochem. Photobiol. B. 2015, 143, 61. (I. F. = 6.25)


    Synthesis, crystal structure and antiproliferative activity of Cu(II) nalidixic acid-DACH conjugate: Comparative in vitro DNA/RNA binding profile, cleavage activity and molecular docking studies.   Eur. J. Med. Chem. 2014, 81, 76. (I. F.= 6.51)